GLP-1s are shaping how people eat, drink, shop, and exercise, and brands need to be paying close attention to these trends. Also referencing the KFF survey, Shil Kothari, president at Gateway Health Alliances Inc., Fairfield, Calif., explains that the awareness of GLP-1s mean that beverage manufacturers must play a proactive role in offering solutions that support those using these medications
Clinical translation challenges Regulatory considerations MNMs have demonstrated excellent therapeutic potential in diseases such as peptic ulcers, IBD, and CRC, owing to their autonomous movement and targeted delivery
Why this happens Both drugs belong to the same family (NSAIDs)
Payer organizations across North America and Europe have increasingly approved Semaglutide for first-line therapy rather than restricting use to treatment-resistant cases, substantially expanding addressable patient populations